Adoptive cell therapies as early treatment options
AssigneeMemorial Sloan Kettering Cancer Center
InventorsJae H. Park, Isabelle Riviere, Xiuyan Wang, Terence Purdon, Michel Sadelain, Renier J. Brentjens
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for providing early cell therapy options to subjects, offering the potential benefit of avoiding higher risk treatment modalities.
Claims76
A method of treatment comprising:
- (a) administering to a subject having a disease or condition a dose of cells expressing a recombinant antigen receptor, which is optionally a chimeric antigen receptor;
- and
- (b) not administering a hematopoietic stem cell transplant (HSCT) to the subject subsequently to administering the antigen receptor-expressing cells and/or not administering an HSCT to the subject within about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or about 1 year subsequently to the initiation of the administration in (a), and/or wherein the subject is not administered an HSCT subsequently to the administration of the cells or within about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or about 1 year subsequently to the initiation of the administration in (a) and/or, not so-administering HSCT in the absence of relapse of the subject, optionally following a clinical remission.
A method of treatment comprising administering to a subject that has a disease or condition and is HSCT-naïve a dose of cells expressing a recombinant antigen receptor, which is optionally a chimeric antigen receptor, wherein the subject is thereafter maintained as HSCT-naive for at least about 1, 2, 3, 4, 5, 6, 9, or 12 months following the initiation of the administration of the dose of cells.
A method of treatment, comprising administering to a subject having a disease or condition a dose of cells expressing a recombinant antigen receptor, wherein the subject does not receive and/or has not received a hematopoietic stem cell transplant (HSCT) subsequently to the initiation of the administering of the antigen receptor-expressing cells and/or prior to the initiation of the administration of the antigen-receptor cells, and/or contemporaneously with the initiation of the administration of the antigen receptor-expressing cells.
A method of treatment, comprising administering to a subject having a cancer exhibiting morphologic disease a dose of cells expressing a recombinant antigen receptor, wherein the subject does not receive a hematopoietic stem cell transplant (HSCT) subsequent to the administration of the antigen receptor-expressing cells.
A method of treatment, comprising:
- (a) selecting a subject with a disease or condition who (i) has not (A) received a hematopoietic stem cell transplant (HSCT), (B) received an HSCT since diagnosis of the disease or condition, (C) been administered a therapy for said disease or condition, (D) been administered a therapy for said disease or condition other than induction chemotherapy, (E) been administered a therapy of said disease or condition other than consolidating therapy and/or a prior dose of the cells and/or (ii) is an adult;
- and/or (iii) exhibits morphologic disease or a disease burden above a certain threshold;
- and/or (iv) is not a candidate for HSCT;
- and/or (v) is not intended to or set to receive HSCT therapy;
- and
- (b) administering to the subject a dose of cells expressing a recombinant antigen receptor, which is optionally a chimeric antigen receptor.
A method of treatment, comprising:
- (a) selecting a subject having a cancer exhibiting morphologic disease or selecting a subject having minimal disease;
- (b) administering to the subject a dose of cells expressing a recombinant antigen receptor;
- and
- (c) not administering a hematopoietic stem cell transplant (HSCT) to the subject subsequently to administering the antigen receptor-expressing cells.
Dependencies are inferred from the claim text.